Our modular FHAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.

The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

At Sonnet BioTherapeutics, we are developing targeted immuno-oncology drugs that turn ‘cold’ tumors ‘hot’. Our proprietary FHAB™ (Fully Human Albumin-Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs